Opaleye Management’s Agios Pharmaceuticals AGIO Stock Holding History

Opaleye Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-130,000	Closed	-$10M	–	48
2018 Q3	$10M	Hold	130,000	–	–	2.55%	10
2018 Q2	$10.9M	Hold	130,000	–	–	2.83%	10
2018 Q1	$10.6M	Hold	130,000	–	–	3.04%	8
2017 Q4	$7.43M	Hold	130,000	–	–	2.38%	13
2017 Q3	$8.68M	Hold	130,000	–	–	3.07%	10
2017 Q2	$6.69M	Hold	130,000	–	–	2.79%	13
2017 Q1	$7.59M	Hold	130,000	–	–	3.78%	6
2016 Q4	$5.42M	Hold	130,000	–	–	3.2%	7
2016 Q3	$6.87M	Buy	130,000 +45,000	+53%	+$1.96M	3.59%	5
2016 Q2	$3.56M	Sell	85,000 -20,000	-19%	-$988K	2.38%	14
2016 Q1	$4.26M	Buy	+105,000	New	+$4.49M	2.66%	14
2015 Q2	–	Sell	-90,000	Closed	-$8.49M	–	47
2015 Q1	$8.49M	Sell	90,000 -23,500	-21%	-$2.63M	3.94%	7
2014 Q4	$12.7M	Hold	113,500	–	–	6.43%	2
2014 Q3	$6.96M	Sell	113,500 -1,500	-1%	-$64.7K	5.43%	5
2014 Q2	$5.27M	Buy	+115,000	New	+$4.69M	4.54%	10

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Opaleye Management's AGIO Position: Q4 2018 in Review

Opaleye Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2018, closing a stake of 130,000 shares — an estimated $10M sold.

Opaleye Management first reported a position in AGIO in Q2 2014 and held it in 15 quarters. The position peaked at $12.7M in Q4 2014. 196 funds tracked by Wall St. Rank hold AGIO as of Q4 2018.

Opaleye Management reported no remaining Agios Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Opaleye Management sold 130,000 Agios Pharmaceuticals shares in Q4 2018, an estimated $10M.
Opaleye Management first reported a position in Agios Pharmaceuticals in Q2 2014 and held it in 15 quarters.
Opaleye Management's Agios Pharmaceuticals position peaked at $12.7M in Q4 2014.
196 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2018.

Based on Opaleye Management's 13F filing for Q4 2018, filed 14 Feb 2019.